D. E. Shaw & Co., Inc. Ngm Biopharmaceuticals Inc Transaction History

D. E. Shaw & Co., Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.31 $8,620 - $18,822	-14,368 Reduced 4.46%	308,104 $264,000
Q3 2023 Nov 14, 2023	SELL	$1.05 - $3.37 $34,038 - $109,248	-32,418 Reduced 9.13%	322,472 $345,000
Q2 2023 Aug 14, 2023	BUY	$2.44 - $4.53 $189,871 - $352,506	77,816 Added 28.08%	354,890 $919,000
Q1 2023 May 15, 2023	BUY	$3.72 - $5.4 $573,318 - $832,237	154,118 Added 125.34%	277,074 $1.13 Million
Q4 2022 Feb 14, 2023	SELL	$3.41 - $12.93 $55,586 - $210,771	-16,301 Reduced 11.71%	122,956 $617,000
Q3 2022 Nov 14, 2022	SELL	$12.59 - $17.67 $272,044 - $381,813	-21,608 Reduced 13.43%	139,257 $1.82 Million
Q2 2022 Aug 15, 2022	BUY	$10.58 - $17.5 $1.03 Million - $1.71 Million	97,468 Added 153.74%	160,865 $2.06 Million
Q1 2022 May 16, 2022	BUY	$13.81 - $18.6 $46,484 - $62,607	3,366 Added 5.61%	63,397 $967,000
Q4 2021 Feb 14, 2022	BUY	$17.26 - $22.02 $258,088 - $329,265	14,953 Added 33.17%	60,031 $1.06 Million
Q3 2021 Nov 15, 2021	SELL	$20.15 - $26.19 $1,209 - $1,571	-60 Reduced 0.13%	45,078 $948,000
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $526,347 - $1.05 Million	34,950 Added 343.05%	45,138 $890,000
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $254,598 - $325,302	10,188 New	10,188 $296,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.